Literature DB >> 19404550

Regulation of urokinase receptor function and pericellular proteolysis by the integrin alpha(5)beta(1).

Rosemary Bass1, Vincent Ellis.   

Abstract

Interactions between the uPA receptor (uPAR) and various integrins, including alpha(5)beta(1), are known to modulate integrin-dependent cell adhesion, and we have shown that the integrin-associated tetraspanin protein CD82 down-regulates uPAR-dependent plasminogen activation by affecting alpha(5)beta(1) cellular localisation. Here we have investigated whether overexpression of alpha(5)beta(1) directly affects uPAR-dependent pericellular proteolysis. CHO cells overexpressing alpha(5)beta(1) were found to activate plasminogen at a rate up to 18-fold faster than B2CHO cells which are alpha(5)-deficient. This effect was dependent on the activation state of alpha(5)beta(1), as it was maximal in the presence of Mn(2+). To determine the role of uPAR-alpha(5)beta(1) interactions in this effect, we determined the adhesion of these cells to immobilised soluble uPAR (suPAR). Neither cell-type was found to adhere to suPAR, but both cell types were found to adhere to an anti-uPAR monoclonal antibody in a uPAR- and integrin-dependent manner. This adhesion was 10-fold greater in the absence of alpha(5)beta(1), possibly implicating the involvement of non-alpha(5)-integrins. Soluble forms of the various components were used to investigate the molecular basis of these effects, but no direct interactions could be demonstrated between alpha(5)beta(1) and either uPAR, uPA or uPA-uPAR complex. This suggests that assembly of these components on the plasma membrane is required to influence uPAR function, increasing uPAR-dependent pericellular proteolysis and decreasing uPAR-dependent cell adhesion. These interactions may be modified by other integrins, suggesting a complex interplay between uPAR and integrins on the cell surface with the potential to regulate invasive cell migration.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19404550

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  7 in total

1.  Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.

Authors:  Timmy Mani; Fang Wang; William Eric Knabe; Anthony L Sinn; May Khanna; Inha Jo; George E Sandusky; George W Sledge; David R Jones; Rajesh Khanna; Karen E Pollok; Samy O Meroueh
Journal:  Bioorg Med Chem       Date:  2013-01-09       Impact factor: 3.641

Review 2.  Regulation of cell signalling by uPAR.

Authors:  Harvey W Smith; Chris J Marshall
Journal:  Nat Rev Mol Cell Biol       Date:  2010-01       Impact factor: 94.444

3.  Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome.

Authors:  G Tzanakaki; M Paparoupa; M Kyprianou; A Barbouni; J Eugen-Olsen; J Kourea-Kremastinou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-05       Impact factor: 3.267

4.  A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.

Authors:  Degang Liu; Donghui Zhou; Bo Wang; William Eric Knabe; Samy O Meroueh
Journal:  ACS Chem Biol       Date:  2015-03-31       Impact factor: 5.100

5.  Binding of extracellular maspin to beta1 integrins inhibits vascular smooth muscle cell migration.

Authors:  Rosemary Bass; Laura Wagstaff; Lorna Ravenhill; Vincent Ellis
Journal:  J Biol Chem       Date:  2009-07-28       Impact factor: 5.157

6.  Integrins and p53 pathways in glioblastoma resistance to temozolomide.

Authors:  Sophie Martin; Hana Janouskova; Monique Dontenwill
Journal:  Front Oncol       Date:  2012-10-31       Impact factor: 6.244

7.  Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).

Authors:  Xiang Xu; Yuan Cai; Ying Wei; Fernando Donate; Jose Juarez; Graham Parry; Liqing Chen; Edward J Meehan; Richard W Ahn; Andrey Ugolkov; Oleksii Dubrovskyi; Thomas V O'Halloran; Mingdong Huang; Andrew P Mazar
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.